Suppr超能文献

临床试验方案在欧盟和美国获得批准后研究伦理委员会的作用:对国际和地区规范文件的描述性内容分析。

The role of research ethics committees after the approval of clinical trial protocols in the EU and the USA: a descriptive content analysis of international and regional normative documents.

机构信息

Center for Medical Ethics, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.

Faculty of Health and Social Sciences, University of South-Eastern Norway, Kongsberg, Norway.

出版信息

Curr Med Res Opin. 2021 Jun;37(6):1061-1069. doi: 10.1080/03007995.2021.1905621. Epub 2021 Apr 16.

Abstract

AIM

To conduct a descriptive content analysis of normative documents on the role of research ethics committees (RECs) after the approval of clinical trial protocols. The question to be addressed is whether and to what extent normative documents support a monitoring role for RECs in the United States and the European Union.

DESIGN

A qualitative content analysis of 19 normative documents on clinical research as outlined by the International Compilation of Human Research Standards 2020 edition and other related documents for the EU and USA.

RESULTS

After the approval of research protocols, RECs' general role is to receive reports from researchers on the trials' progress. Additionally, RECs receive notifications of protocol amendments, deviations and, to a lesser extent, violations, which is the remit of the regulatory/competent authorities. RECs are expected to issue opinions on clinical trials' progress and give supplemental opinions/approval or withdraw/suspend/terminate previous favorable opinions on adverse events or safety concerns that may arise. RECs are to receive an end of the trial report.

CONCLUSION

The role of RECs post approval of protocols is to protect human participants through activities such as continuing review of: (a) progress reports, (b) notifications of significant protocol amendments, (c) adverse events, (d) protocol deviations, and (e) protocol violations. Although some international guidelines such as the Declaration of Helsinki emphasize the right to monitor, RECs' predominant activity is document review. In the USA, RECs are authorized to issue approvals and terminate/suspend previously issued approvals. However, in the EU, the approach is to relegate to member states to decide the extent of legislative power they wish to give to the RECs. The REC's opinion on the end of trial report is identified as an area for further exploration.

摘要

目的

对已批准临床试验方案后研究伦理委员会(RECs)作用的规范性文件进行描述性内容分析。要解决的问题是,规范性文件是否以及在何种程度上支持美国和欧盟 RECs 的监督作用。

设计

对 2020 年版《国际人类研究标准汇编》和欧盟及美国其他相关文件中概述的 19 项临床研究规范性文件进行定性内容分析。

结果

研究方案批准后,RECs 的一般作用是接收研究人员关于试验进展的报告。此外,RECs 还会收到方案修订、偏离以及在较小程度上的违规通知,这是监管/主管当局的职责。RECs 应就临床试验进展发表意见,并在出现可能的不良事件或安全问题时,补充意见/批准或撤回/暂停/终止先前对试验的有利意见。RECs 应收到试验结束报告。

结论

方案批准后 RECs 的作用是通过以下活动保护人类参与者:(a)持续审查进展报告;(b)重大方案修订通知;(c)不良事件;(d)方案偏离;和(e)方案违规。尽管《赫尔辛基宣言》等一些国际准则强调了监测的权利,但 RECs 的主要活动仍是文件审查。在美国,RECs 有权批准并终止/暂停先前发布的批准。然而,在欧盟,方法是将决定赋予 RECs 的立法权的范围下放给成员国。REC 对试验结束报告的意见被确定为进一步探讨的领域。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验